Seres Therapeutics grants 25,000 stock options to officer

Seres Therapeutics, Inc. reported that officer Matthew R. Henn received a grant of stock options for 25,000 shares of common stock.

Rhea-AI Filing Summary

Seres Therapeutics, Inc. reported that officer Matthew R. Henn received a grant of stock options for 25,000 shares of common stock. The options carry an exercise price of $9.13 per share and expire on March 3, 2036. According to the vesting terms, 25% of the options vest on March 2, 2027, with the remaining shares vesting in 12 equal quarterly installments thereafter, contingent on continued service.

Insights

Equity Compensation Analyst

Routine option grant aligns the officer’s incentives with long-term share performance.

The filing shows Matthew R. Henn received an option grant for 25,000 shares at an exercise price of $9.13, expiring on March 3, 2036. This is coded as a grant/award acquisition rather than an open-market purchase.

The vesting structure is back-weighted: 25% of the options vest on March 2, 2027, and the balance vests in 12 equal quarterly installments afterward. This design encourages longer-term retention and performance alignment, since most value unlocks over several years.

Because this is a standard compensation grant with no related sale or tax disposition, it is generally viewed as neutral information, showing continued use of equity incentives without signaling a change in insider sentiment.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Henn Matthew R

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Key Figures

Option Shares Granted: 25,000 shares Exercise Price: $9.13 per share Post-Grant Option Holdings: 25,000 options +3 more

6 metrics

Option Shares Granted 25,000 shares Stock option (right to buy) granted to officer Matthew R. Henn

Exercise Price $9.13 per share Conversion or exercise price of the granted stock option

Post-Grant Option Holdings 25,000 options Total derivative shares following the reported transaction

Initial Vesting Date March 2, 2027 25% of the option shares vest on this date

Expiration Date March 3, 2036 Expiration of the granted stock option

Quarterly Vesting Tranches 12 installments Remaining 75% of shares vest in 12 equal quarterly installments

Key Terms

Stock Option (right to buy), grant/award acquisition, exercise price, vesting

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 9.1300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option will vest as to 25% of the shares on March 2, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henn Matthew R

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.13	07/08/2026		A		25,000		(1)	03/03/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

President and Chief Scientific Officer

	/s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)